Low Hospital Admission Rates Following POIC-Based Outpatient Treatment with Intravenous Antibiotics

PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) provided by a physician office infusion center revealed an overall low 30-day hospital admission rate of 6.8% compared to 26% previously reported. This collaborative, retrospective study reviewed charts of 600 randomly selected patients with a range of diagnoses from ten nationwide Infectious Disease physician office infusion centers and determined any unplanned hospital admission and readmission within 30 days of outpatient treatment. The results were further analyzed for factors that could potentially predict 30-day hospital admissions. As a result, 41 patients (6.8%) were admitted to the hospital including 32 patients previously hospitalized and 9 patients without prior hospital stay. The indications for hospital admissions were: worsening infections (59%), reasons unrelated to the primary infection (22%), new infections (12%) and device-related issues (7%). Significantly increased odds to be admitted to the hospital within 30 days of OPAT were calculated for patients with bacteremia (odds ratio 2.9, 95% confidence interval 1.4 to 6.1, p=0.004) and prior 6-month hospitalization (odds ratio 2.1, 95% confidence interval 1.1 to 4.0, p=0.036). This study suggests that outpatient treatment at a physician office infusion center provides optimal therapy with a high potential to prevent costly admissions and return visits to the hospital. To learn more, click here.

This study was presented at IDWeek 2014™. For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected].

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

ABOUT IDWeek 2014
IDWeek 2014 is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2014 took place October 8-12 at the Philadelphia Convention Center at Philadelphia, Pennsylvania. The full name of the meeting is IDWeek 2014™. For more information, visit www.idweek.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.